Torrent Pharma’s Q2 Results Draw Mixed Reactions From Brokerages

Analysts have given mixed reactions to Torrent Pharmaceuticals, which reported a 16% year-on-year increase in second-quarter revenue to Rs 26,600 crore, more than half of which came from India. Kotak and JM Financial have remained cautious on Torrent Pharma with unchanged ‘REDUCE’ and ‘HOLD’ ratings respectively. While JM Financial has not outlined estimate changes, Kotak […]

COVID-19: Eli Lilly lets Torrent Pharma manufacture Bartinicib

A week after Natco Pharma sought a compulsory license from government of India to manufacture COVID treatment drug Baricitinib, the US firm holding the rights to the drug — Eli Lilly — seems to have agreed to let several companies to manufacture and sell the drug. Baricitinib is used for treating joint inflammation in rheumatoid […]

Torrent Pharma’s Indrad plant gets ‘procedural observations’ by USFDA

Ahmedabad-based Torrent Pharmaceuticals said its manufacturing facility at Indrad in Gujarat was subject to certain ‘procedural observations’ by the United States Food and Drug Administration following a routine inspection. The pharma company did not quantify how many observations were made by the US health regulator. Procedural observations are referred to as deficiencies in standard operating […]

Torrent Pharma completes acquisition of Unichem’s branded India business

Torrent Pharmaceuticals said it completed its previously announced acquisition of the branded formulation business of Unichem Laboratories for India and Nepal, including its Sikkim manufacturing facility. The deal was signed on 3rd November, 2017. With this, Torrent has entered the list of top pharma firms in the Indian market. “From today, Torrent begins the Integration […]

Exit mobile version